评估Rybrevant与Lazcluze联用，与活性对照奥希替尼（osimertinib）相比的疗效和安全性。研究的主要终点为根据RECISTv1.1标准、经独立盲法中央评审（BICR ...

J Thorac Oncol. 2023 May;18(5):657-663. [3]Nassar AH, et al. Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non ...